MRPL27 Antibody

What is MRPL27 and what cellular functions does it perform?

MRPL27 (Mitochondrial Ribosomal Protein L27) is a nuclear-encoded protein that plays a critical role in mitochondrial protein synthesis. It functions as a component of the large 39S subunit of mitochondrial ribosomes (mitoribosomes). Mitoribosomes have a distinctive composition compared to prokaryotic ribosomes, with approximately 75% protein to rRNA composition, whereas this ratio is reversed in prokaryotic ribosomes. Another notable difference is that mammalian mitoribosomes lack the 5S rRNA found in prokaryotic ribosomes. MRPL27 contributes to the structural integrity and functionality of mitoribosomes, which are essential for translating mitochondrial mRNAs encoding components of the oxidative phosphorylation system .

What species reactivity can be expected with commercially available MRPL27 antibodies?

Currently available MRPL27 antibodies demonstrate consistent reactivity with human, mouse, and rat samples, as confirmed through validated testing. This cross-species reactivity is particularly valuable for comparative studies across mammalian models. The 14765-1-AP antibody, for example, has been specifically tested and confirmed to react with human, mouse, and rat MRPL27 proteins . When using these antibodies for other species, preliminary validation is recommended as mitoribosomal proteins can vary significantly in sequence between species, potentially affecting antibody recognition .

What are the structural characteristics and molecular weight considerations for MRPL27 detection?

When working with MRPL27 antibodies, researchers should note the discrepancy between calculated and observed molecular weights. The calculated molecular weight of MRPL27 is approximately 16 kDa, but it typically appears at around 10 kDa on Western blots . This difference is important for accurate band identification and experimental validation. The protein has a specific sequence (MASVVLALRTRTAVTSLLSPTPATALAVRYASKKSGGSSKNLGGKSSGRR...) that serves as the immunogen for antibody production . Understanding these characteristics is crucial for proper experimental design and results interpretation, particularly when multiple bands appear on immunoblots.

What applications are validated for MRPL27 antibodies and what are the optimal dilution parameters?

MRPL27 antibodies have been validated for multiple experimental applications with specific dilution recommendations for optimal results:

These dilution ranges should be considered starting points, as optimal concentrations may vary depending on sample type, detection method, and experimental conditions. It is recommended that researchers titrate the antibody in each testing system to obtain optimal results .

How should MRPL27 antibodies be stored and handled to maintain reactivity and performance?

For optimal preservation of antibody activity, MRPL27 antibodies should be stored at -20°C, where they typically remain stable for one year after shipment. The storage buffer generally consists of PBS with 0.02% sodium azide and 50% glycerol at pH 7.3, which helps maintain antibody integrity. For the 14765-1-AP antibody specifically, aliquoting is noted as unnecessary for -20°C storage, which can simplify laboratory handling. Some preparations in 20μl sizes contain 0.1% BSA as a stabilizer . When working with the antibody, minimize freeze-thaw cycles as repeated freezing and thawing can degrade antibody performance. After thawing, keep the antibody on ice during experimental procedures to maintain its structural integrity and binding capacity.

What are the recommended protocols for optimizing MRPL27 detection in immunofluorescence experiments?

For successful immunofluorescence detection of MRPL27, follow these methodological considerations:

• Cell Preparation: Fix cells using 4% paraformaldehyde for 15 minutes at room temperature, followed by permeabilization with 0.5% Triton X-100 for 10 minutes.

• Blocking: Use 5% normal serum in PBS for 1 hour to reduce non-specific binding.

• Primary Antibody Incubation: Apply MRPL27 antibody at a starting dilution of 1:400 (range 1:200-1:800) and incubate overnight at 4°C .

• Secondary Antibody: Use fluorophore-conjugated secondary antibodies at manufacturer-recommended dilutions (typically 1:500-1:1000).

• Counterstaining: To confirm mitochondrial localization, co-stain with established mitochondrial markers.

• Validation Controls: Always include a negative control (omitting primary antibody) and, if possible, a positive control using cells known to express MRPL27, such as A431 cells which have been validated for MRPL27 detection .

• Signal Optimization: If signal strength is inadequate, consider longer primary antibody incubation times or slight increases in antibody concentration.

How can researchers validate MRPL27 antibody specificity for mitochondrial localization studies?

Validating MRPL27 antibody specificity for mitochondrial localization requires a multi-faceted approach:

• Co-localization Studies: Perform dual immunofluorescence with established mitochondrial markers (e.g., TOM20, COXIV) to confirm MRPL27 mitochondrial localization.

• Mitochondrial Fractionation: Isolate mitochondrial fractions from whole cell lysates and conduct Western blotting to confirm enrichment of MRPL27 in mitochondrial fractions versus cytosolic fractions.

• siRNA Knockdown Validation: Perform siRNA-mediated knockdown of MRPL27 and demonstrate reduced signal in both Western blotting and immunofluorescence to confirm antibody specificity.

• Mitochondrial Translation Inhibition: Treat cells with mitochondrial translation inhibitors (e.g., chloramphenicol) and assess changes in MRPL27 distribution patterns.

• Electron Microscopy with Immunogold Labeling: For ultra-high resolution validation, use immunogold labeling to precisely localize MRPL27 to mitochondrial ribosomes.

This comprehensive validation ensures that the observed signals truly represent mitochondrial MRPL27 and not cross-reactive proteins or artifacts.

What are the considerations for using MRPL27 antibodies in mitoribosome assembly and function studies?

When investigating mitoribosome assembly and function using MRPL27 antibodies, researchers should consider several methodological aspects:

• Temporal Analysis: Use MRPL27 antibodies in pulse-chase experiments to track the incorporation of newly synthesized MRPL27 into mitoribosomes, providing insights into assembly kinetics.

• Interaction Partners: Combine MRPL27 immunoprecipitation with mass spectrometry to identify interaction partners within the mitoribosomal complex and assembly intermediates.

• Structural Context: Consider that MRPL27 is part of the 39S large subunit in a complex with approximately 75% protein to rRNA composition , which affects experimental design for structural studies.

• Functional Assays: When assessing mitoribosomal function, pair MRPL27 detection with mitochondrial translation assays (35S-methionine incorporation) to correlate structural observations with functional outcomes.

• Species Variations: Account for the fact that mitoribosomal proteins differ significantly in sequence between species , which may affect experimental interpretations in cross-species studies.

• Disease Models: In pathological contexts, assess both MRPL27 levels and mitoribosomal integrity, as disruptions in either can affect mitochondrial translation efficiency.

How can researchers distinguish between specific MRPL27 detection and non-specific binding in complex tissue samples?

To distinguish specific MRPL27 signals from non-specific binding in complex tissues:

• Blocking Optimization: Evaluate different blocking agents (BSA, normal serum, commercial blockers) to identify optimal conditions that minimize background while preserving specific signal.

• Antibody Pre-absorption: Pre-incubate the antibody with recombinant MRPL27 protein prior to tissue application; this should significantly reduce specific staining while non-specific binding remains unchanged.

• Titration Analysis: Perform systematic antibody dilution series (e.g., 1:20, 1:50, 1:100, 1:200) to identify the optimal concentration where specific signal is maintained but background is minimized .

• Multiple Antibody Validation: When possible, use two different MRPL27 antibodies recognizing distinct epitopes; overlapping signals strongly suggest specific detection.

• Genetic Controls: Use tissues from MRPL27 knockout or knockdown models as negative controls.

• Isotype Controls: Include appropriate rabbit IgG isotype controls at matching concentrations to identify non-specific binding of the antibody class.

• Tissue-Specific Autofluorescence Control: For fluorescent detection, include unstained tissue sections to identify autofluorescence patterns distinct from antibody-specific signals.

How should researchers address the molecular weight discrepancy between calculated (16 kDa) and observed (10 kDa) MRPL27 in Western blots?

The discrepancy between calculated (16 kDa) and observed (10 kDa) molecular weights for MRPL27 in Western blots requires methodical investigation:

• Protein Processing: The lower observed molecular weight may indicate post-translational processing, such as removal of a mitochondrial targeting sequence after import into mitochondria.

• Experimental Validation: Confirm band identity through:

  • Comparison with recombinant full-length MRPL27 protein

  • siRNA knockdown to demonstrate specific reduction of the 10 kDa band

  • Mass spectrometry analysis of the excised band to confirm identity

• Loading Controls: Include mitochondrial markers of known molecular weight to validate size determinations across the blot.

• Gel Percentage Optimization: Use 12-15% polyacrylamide gels for optimal resolution in this low molecular weight range.

• Alternative Antibodies: If available, test alternative MRPL27 antibodies targeting different epitopes to confirm consistent detection at 10 kDa.

What positive and negative controls should be included when validating MRPL27 antibody performance in new experimental systems?

Comprehensive validation of MRPL27 antibodies in new experimental systems should include:

Positive Controls:

• Cell lines with confirmed MRPL27 expression (e.g., A431 cells have been validated for MRPL27 detection)

• Tissues with known high mitochondrial content (heart, liver, kidney)

• Recombinant MRPL27 protein or overexpression systems

• Mitochondrial fraction enrichment (should show increased MRPL27 signal compared to whole cell lysate)

Negative Controls:

• siRNA or shRNA knockdown of MRPL27 (should show reduced signal)

• Samples processed with isotype-matched non-specific IgG instead of primary antibody

• Cytosolic fraction (should show minimal MRPL27 compared to mitochondrial fraction)

• Pre-incubation of antibody with immunizing peptide (should abolish specific signal)

System-Specific Controls:

• For species not listed in validated reactivity, include side-by-side comparison with validated species

• For new applications, include samples previously validated in established applications

This systematic approach ensures that observed signals truly represent MRPL27 and helps establish the performance parameters in the specific experimental context.

How can contradictory findings with MRPL27 antibodies across different experimental systems be reconciled?

When confronted with contradictory findings using MRPL27 antibodies across different experimental systems, researchers should implement a systematic troubleshooting approach:

• Antibody Batch Variation: Test different lots of the antibody to identify potential batch-to-batch variability; request certification of batch validation from manufacturers.

• Epitope Accessibility: Consider that different sample preparation methods may affect epitope accessibility. Variations in fixation, permeabilization, or antigen retrieval can significantly impact antibody binding.

• Sample-Specific Factors: Evaluate whether the contradiction relates to sample-specific factors such as:

  • Expression level differences (requiring adjusted exposure times)

  • Post-translational modifications affecting epitope recognition

  • Splice variants present in different systems

  • Species-specific sequence variations at the epitope

• Quantitative Analysis: Apply quantitative methods (densitometry for WB, fluorescence intensity measurements for IF) to determine if differences are qualitative or merely quantitative.

• Multiple Antibody Approach: Use alternative MRPL27 antibodies targeting different epitopes to distinguish antibody-specific issues from true biological differences.

• Orthogonal Validation: Confirm findings using antibody-independent methods such as RNA-level analysis (qPCR, RNA-seq) or mass spectrometry.

• Standardization: Develop and implement standardized protocols across all experimental systems to minimize method-dependent variations.

What is the significance of MRPL27 in cancer research and potential therapeutic applications?

MRPL27's role in cancer research is emerging as significant based on several lines of evidence:

• Expression Patterns: The Human Protein Atlas indicates differential expression of MRPL27 across various cancer types, suggesting potential diagnostic or prognostic value .

• Mitochondrial Translation in Cancer: Cancer cells often exhibit altered mitochondrial function and metabolic reprogramming. As a component of the mitochondrial translation machinery, MRPL27 may contribute to these cancer-specific metabolic adaptations.

• Therapeutic Targeting: Disruption of mitochondrial translation represents a potential anticancer strategy, particularly for tumors reliant on oxidative phosphorylation. MRPL27 could serve as a biomarker for sensitivity to such approaches.

• Precision Medicine Applications: Variations in MRPL27 expression or mutation status across tumor types might inform personalized treatment strategies targeting mitochondrial function.

• Research Methodologies: When investigating MRPL27 in cancer contexts, researchers should:

  • Perform comparative analyses across normal and malignant tissues

  • Correlate MRPL27 levels with mitochondrial translation efficiency

  • Assess associations between MRPL27 expression and patient outcomes

  • Evaluate MRPL27 as a potential biomarker for response to mitochondrially-targeted therapies

This emerging area requires further investigation to fully elucidate MRPL27's role in cancer biology and its potential as a therapeutic target.

How does MRPL27 contribute to mitochondrial diseases and what methodological approaches are recommended for investigating these connections?

MRPL27's integral role in mitochondrial translation positions it as potentially significant in mitochondrial disease pathophysiology:

• Mitochondrial Disease Context: As a component of mitoribosomes, MRPL27 dysfunction could contribute to impaired mitochondrial protein synthesis, affecting oxidative phosphorylation and energy production.

• Methodological Approaches for Investigation:

  • Patient Sample Analysis: Compare MRPL27 levels and mitoribosome assembly in samples from patients with mitochondrial translation defects versus controls.

  • Functional Assays: Measure mitochondrial translation efficiency (35S-methionine incorporation) in relation to MRPL27 levels or mutations.

  • Genetic Models: Create cellular or animal models with MRPL27 knockdown/knockout to assess impacts on mitochondrial function and disease phenotypes.

  • Structure-Function Analysis: Use MRPL27 antibodies to investigate how specific mutations affect incorporation into the mitoribosome complex.

  • Rescue Experiments: Test whether overexpression of wild-type MRPL27 can rescue phenotypes in disease models.

• Technical Considerations:

  • Use tissue-specific approaches, as mitochondrial disease often affects high-energy tissues disproportionately

  • Combine protein-level analysis (using validated MRPL27 antibodies) with functional respiratory chain measurements

  • Consider mitochondrial dynamics and quality control mechanisms when interpreting MRPL27-related findings

This research area represents an important frontier in understanding the molecular basis of mitochondrial diseases and identifying potential therapeutic targets.

What experimental approaches are recommended for investigating MRPL27's interactions with other mitoribosomal proteins?

To elucidate MRPL27's interactions within the mitoribosomal complex, researchers should consider these methodological approaches:

• Co-Immunoprecipitation (Co-IP): Use validated MRPL27 antibodies for pull-down experiments followed by mass spectrometry or Western blotting for known mitoribosomal proteins. This approach requires careful optimization of lysis conditions to preserve native protein complexes.

• Proximity Labeling: Employ BioID or APEX2 fusion proteins with MRPL27 to identify proximal proteins in living cells, providing insights into the spatial organization within mitoribosomes.

• Cryo-Electron Microscopy: Use structural biology approaches combined with immunogold labeling to precisely locate MRPL27 within the mitoribosomal structure and identify its interaction interfaces.

• Crosslinking Mass Spectrometry (XL-MS): Apply protein crosslinking followed by mass spectrometry to identify direct interaction partners of MRPL27 within the intact mitoribosome.

• Fluorescence Resonance Energy Transfer (FRET): Tag MRPL27 and potential interaction partners with appropriate fluorophores to detect protein-protein interactions in living cells.

• Mitoribosome Assembly Assays: Use pulse-chase experiments with MRPL27 antibodies to track incorporation into assembling mitoribosomes and identify assembly intermediates.

• Mutation Analysis: Introduce specific mutations in MRPL27 and assess effects on interactions with other mitoribosomal components using the above methods.

These complementary approaches can provide a comprehensive understanding of how MRPL27 contributes to mitoribosome structure and function through its protein-protein interactions.